Chemotherapy Disrupted Immune Response in Gastric Cancer
New findings explain why certain gastric cancers may respond poorly to standard chemotherapy treatments.
Updated on Sept. 23, 2026 in Cancer
Researchers identified that chemotherapy can trigger Epstein-Barr virus reactivation, which impairs the immune system's ability to organize local defenses in gastric cancer. This discovery, published September 23, 2026, highlights a mechanism that may limit the effectiveness of standard treatments in this specific cancer type.
Why it matters
Understanding how chemotherapy impacts the immune microenvironment helps explain the limited efficacy of standard treatments for Epstein-Barr virus-associated gastric cancer. This research clarifies why tumors may recur and how immune surveillance can be inadvertently disrupted.
A study analyzing 144 samples, including 77 in a single-cell atlas and 11 via spatial transcriptomics, found that chemotherapy triggers viral reactivation. This process impairs tertiary lymphoid structures, which are typically associated with favorable outcomes.
The players
Epstein-Barr virus
A common human herpesvirus known to be associated with specific oncogenic processes including some forms of gastric cancer.
The details
Chemotherapy induces the reactivation of the Epstein-Barr virus, which subsequently activates pattern recognition receptors in neutrophils. This stimulation leads to the formation of neutrophil extracellular traps, a mesh-like structure that inhibits lymphocyte migration and the maturation of tertiary lymphoid structures. These structures are essential for mounting an effective anti-tumor immune response within the tumor microenvironment.
Timeline
September 23, 2026: Article publication
Health Landscape
This research builds upon global tumor microenvironment mapping initiatives to better understand immune resistance. It marks a shift from viewing chemotherapy as a direct tumor-killing agent to recognizing its secondary, complex effects on local immune signaling.
If you or a loved one are navigating a diagnosis of Epstein-Barr virus-associated gastric cancer, discuss the implications of tumor microenvironment research with your oncology team. These findings emphasize the importance of personalized treatment conversations when standard chemotherapy shows limited success.
The takeaway
This analysis reveals how chemotherapy can inadvertently hinder the body's immune defenses in specific gastric cancers. Patients should talk with their physicians about the potential for immune-mediated resistance when evaluating different treatment paths for complex cancers.
Further reading
For more on the complexities of tumor biology and immune response, visit Cancer.
More information
Access the full findings in the peer-reviewed research article.
Source note: This article includes information reported by Nature.
